MOH Molina Healthcare Inc
$207.23
▼ 2.5%Updated Oct 16, 2:25 PM ET
Report Card
MOH at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Weak · 28/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▼ Down 5.0% in the year to Jul 6, 2026
Key Metrics
Market Cap
$11.98B
P/E
62.67x
Forward P/E (est.)
89.53x
ROE
4.4%
Revenue Growth
7.7%
EPS Growth
-83.7%
Profit Margin
0.4%
FCF Yield
8.3%
Debt / Equity
0.98x
ROIC
11.0%
Interest Coverage
7.17x
Current Ratio
1.68x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
28/100
Business Overview
Molina Healthcare Inc (MOH) is a large-cap NYSE-listed company in the Health Care industry, within the Health Care sector, with a market value around $11.98B.
In its latest reported year it generated about $45.43B in revenue and $472.00M in net profit.
Our model rates MOH Weak (28/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedSome durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
13.3% average over the last 3 years
±1.9 pts around 11.7% across 5 years
grew in 7 of the last 9 year-over-year periods
positive in 8 of 10 years
11.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MOH's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MOH trades near $207.23, above its 50-day average ($194.64) and 200-day average ($170.04). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 75 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MOH's is $8.43 (~4.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, MOH found buyers near $190.00 (support) and sellers near $236.26 (resistance); its 52-week range then was $121.06–$242.56. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
13.1%
Revenue moved from $17.78B in 2016 to $45.43B in 2025, a 11.0% compound annual growth rate. The most recent year grew a steady 7.7% year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
12.9%
Operating Margin
1.7%
Net Margin
1.0%
ROE
4.4%
Molina Healthcare Inc keeps about 0.4% of each sales dollar as net profit, with a 12.9% gross margin and 1.7% operating margin. Return on equity is 4.4% and return on invested capital about 11.0%. Thin margins leave less cushion if costs rise.
Debt Analysis
Total Debt
$1.65B
Net Debt
-$3.33B
Net cash position
Net Debt / EBITDA
-4.27x
Debt / Equity
0.98x
Leverage: debt-to-equity is 1.0x, and operating profit covers interest about 7.2x, with a current ratio of 1.7x. That is a moderate, manageable debt load for most businesses. It carries roughly $1.65B of total debt against $4.99B of cash.
Cash Flow Analysis
Operating CF
-$535.00M
Free Cash Flow
-$636.00M
FCF Margin
-1.4%
In the latest year Molina Healthcare Inc produced about -$535.00M of operating cash flow but negative free cash flow as it invested heavily. That is a free-cash-flow yield of about 8.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
Valuation Analysis
P/E
62.67x
P/S
0.26x
P/B
2.19x
EV / EBITDA
8.86x
MOH trades at 62.7x trailing earnings (about 89.5x on estimated forward earnings), 0.3x sales, and 2.2x book value. That is a rich multiple that prices in a lot of future growth.
Metrics vs. Sector Range
Where MOH sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How MOH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, MOH ranks #80 by our overall rating. It trades at a premium versus the sector on earnings (62.7x P/E vs. 26.1x median) with a lower return on equity (4.4% vs. 14.1%) and faster revenue growth (7.7% vs. 7.6%).
P/E vs sector
62.7x
median 26.1x
ROE vs sector
4.4%
median 14.1%
Growth vs sector
7.7%
median 7.6%
Sector rank
#80
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$1,316.62 – $2,182.82
vs. $207.23 today · implied CAGR 45% – 60%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $49.06B | $52.98B | $57.22B | $61.80B | $66.75B |
| Net income | $1.47B | $1.59B | $1.72B | $1.85B | $2.00B |
| EPS | $25.47 | $27.50 | $29.71 | $32.08 | $34.65 |
| Share price (low) | $967.76 | $1,045.18 | $1,128.79 | $1,219.09 | $1,316.62 |
| Share price (high) | $1,604.44 | $1,732.79 | $1,871.42 | $2,021.13 | $2,182.82 |
| CAGR (low–high) | 367% / 674% | 125% / 189% | 76% / 108% | 56% / 77% | 45% / 60% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for MOH:
- Healthy free-cash-flow yield (~8.3%) funds buybacks and dividends.
Bear Case
The case against MOH:
- Thin net margins (0.4%) leave little room for error.
- A rich 62.7x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (28/100).
Key Risks
Valuation risk — at 62.7x earnings, disappointing results could compress the multiple.
Margin risk — thin profitability (0.4%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen weakly: Molina Healthcare Inc is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 62.7x earnings, which our model scores Weak (28/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
MOH's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
MOH — frequently asked questions
Is MOH a good stock to buy?
We don't give buy or sell advice. Our model rates Molina Healthcare Inc Weak (28/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is MOH's rating on The Stocks School?
Molina Healthcare Inc currently scores 28/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does MOH's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Molina Healthcare Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for MOH calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this MOH analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell MOH. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.